jeudi 28 septembre 2017

Onco Actu du 28 septembre 2017

1. Biologie

How do cancer cells release their “brakes” to allow division? [UNC]

5. Traitements

High-precision radiotherapy for prostate cancer 'shows promise' [NHS Choices]

5.12.2 Immunothérapies - CAR-T

Rubius names ex-GlaxoSmithKline VP as CMO as CAR-T rivals near clinic [FierceBiotech]

5.12.5 Immunothérapies - Pharma

Merck adds real patient to 'TRU' Keytruda TV ad [FiercePharma]

5.12.7 Immunothérapies - vaccins

PPD to run first-in-human trial of Treos’ lead cancer vaccine [FierceBiotech]

5.2 Pharma

Mateon cuts cancer combo test, costs as it refocuses efforts [FierceBiotech]

Mateon Therapeutics Announces Termination of Focus Study in Ovarian Cancer and Restructuring to Prioritize OXI4503 for AML [Mateon]

Small is big: Pharma’s R&D brain drain continues as GSK’s Chris Carpenter jumps to upstart Rubius [EndPoints]

5.2.3 Pharma - économie

Pharma's pricing pledges? Maybe they weren't such a good idea in the first place, experts say [FiercePharma]

5.9.5 IASLC

Takeda to Feature ALUNBRIGTM (brigatinib) Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer [Takeda]

Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer [BMS]

6. Lutte contre les cancers

Can Heart Disease Shed Light on Cancer? [NY Times]

6.4 Médico-éco

JAMA Forum: The High Costs of Unnecessary Care [JAMA]

6.7.2 Applis

Apple, J&J join FDA program to fast-track digital health apps [FierceBiotech]